NCT04506138View on ClinicalTrials.gov

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Camrelizumab

Camrelizumab 200mg D1, D22

DRUG

Paclitaxel for Injection (Albumin Bound)

Paclitaxel for Injection (Albumin Bound) 100mg/m\^2 D1, D8, D22, D29

DRUG

Carboplatin

Carboplatin AUC5 D1, D22

Trial Locations (1)

310022

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER